Technical analysis indicates that selling in Oncosil (ASX: OSL) is overdone, likely driven in the past by the broader performance of the ASX and more recently by higher interest rates and inflation. However, the sell-off will taper soon as the chart suggests that selling could likely be overdone. This represents a very good buy opportunity for investors and with expansion and commercialization tend to continue in 2024, the stock could be gearing for a reversal.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
-0.005(0.50%) |
Mkt cap ! $14.29M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.00 | 99.5¢ | $19.85K | 19.85K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6255 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 18062 | 2 |
View Market Depth
| Last trade - 10.05am 23/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |